This paper covers a unique program created in the United Kingdom between the MRC Cyclotron Unit and the CRC Phase I and II drug development committee to investigate the potential of tracer kinetic studies to investigate in vivo tumor and normal tissue kinetics, molecular interactions, pathways, and mechanism of action of novel anti-cancer agents. Positron emission tomography technology offers great potential in streamlining anti-cancer drug development programs, however, significant investment in new methodology and multidisciplinary teams is necessary.
StraussL. Kinetics and applications of F-18-fluorouracil in colorectal tumours. In: PET for drug development and evaluation.ComarD, Ed. Dordrecht, Boston, London: Kluwer Academic Publishers; 1995: 327–340.
2.
HarteRJAMatthewsJCFlavinABrockCSOsmanSLuthraSKBrownGBradyFJonesTBleehanNPriceP. Pre-phase I tracer kinetic studies in humans can contribute to new drug evaluation. 9th NCI-EORTC Symposium on new drugs in cancer therapy. 1996:167;50.
3.
BrockCSMatthewsJCBrownGNewlandsESPriceP. Demonstration and quantitation of temozolomide uptake in vivo in human brain tumours. 9th NCI-EORTC Symposium on new drugs in cancer therapy. 1996:488;137.
4.
PricePJonesT. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?. Eur J Cancer.1995;31A(12):1924–1927.
5.
WellsPGunnRMeikleSSteelCNewellDRJonesTPriceP. The use of [2-11C]thymidine tracer kinetic studies in the assessment of anti-cancer therapy. Br J Cancer.1996;April Supplement.
6.
CunninghamVJJonesT. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab.1993; 13:15–23.
